South Africa-based private hospital group Mediclinic International’s major shareholder Remgro signed an agreement to purchase a 29.9% stake in UK-based Spire Healthcare Group from Cinven for £431.7m.
Under the deal, Remgro, through its wholly-owned subsidiary Remgro Jersey, will acquire 119,923,335 ordinary shares in Spire at a price of 360p per share.
Spire Healthcare operates 39 hospitals, 13 clinics and one radiotherapy cancer centre across England, Wales and Scotland. It offers services in areas, including orthopaedics, gynaecology, cardiology, neurology, oncology and general surgery, as well as diagnostic services such as imaging and pathology.
Royal Philips entered a multi-year, $500m partnership with US-based Westchester Medical Center Health Network (WMCHealth), in a bid to improve patient care across New York’s Hudson Valley.
Under the deal, Philips will provide enterprise managed services, including a wide range of clinical and business consulting services, to WMCHealth.
The partnership will work together to improve services in all areas, comprising radiology, cardiology, neurology, oncology and paediatrics.
The expansion works for Marin General Hospital’s $394m project started in Greenbrae, California, US.
LBL Architects designed the expansion project to replace the existing hospital. The new project will feature a four-storey and 260,000ft² hospital building, as well as a five-storey and 100,000ft² ambulatory services building and two parking structures.
The project was designed to include a new emergency drop-off area and a bigger loading dock to manage additional traffic and equipment.
Losinger Marazzi, a Swiss subsidiary of Bouygues Construction, plans to design and build a new LimmiViva hospital in the town of Schlieren, near Zurich.
The Spitalverband Limmattal hospital group’s new facility will be developed with an investment of €175m.
The project will involve the construction of an eight-storey building with 50,000m² of space that can accommodate 200 beds.
The company will begin the fitting out phase of the project in the third quarter of 2016. The facility is expected to become operational in 2018.
Acadia Healthcare acquired 17 inpatient behavioural health facilities with 500 beds in the UK and US for $145m.
Acadia acquired behavioural health operations of Care UK that comprise 15 inpatient facilities with 300 beds.
The acquired facilities provide behavioural health services to children, adolescents and adults.
Acadia operates 224 behavioural health facilities with 9,000 beds in 37 states in the US, the UK and Puerto Rico.
Bank of Georgia’s healthcare subsidiary Georgia Healthcare Group entered a binding memorandum of understanding to acquire a 50% equity stake in GNCo.
Once the deal concludes, Georgia Healthcare’s portfolio will include 41 healthcare facilities and 2,670 beds across Georgia.
The facility was acquired as part of the firm’s strategy to expand its healthcare services business through targeted hospital acquisitions, focusing on Tbilisi.
South Korean authorities temporarily closed two hospitals in the country’s capital Seoul, to control the spread of the Middle East Respiratory Syndrome (MERS) virus.
Konkuk University Medical Centre, where four cases have been reported, ceased to take new patients.
Samsung Medical Centre (SMC), which has remained closed since 14 June, will suspend its operations indefinitely, AFP reported.
According to the latest WHO figures, 178 cases of MERS have been reported from South Korea and one from China. There have been 27 deaths so far.
Cancer Research UK launched Major Centres at its Oxford, Manchester and Cambridge hubs to support research in early detection of cancer and personalised medicine.
The three Major Centres will receive £5m each for collaborative research and ‘bridging the gap between innovative laboratory work and benefits for patients’.
Cancer Research UK executive director for research funding Dr Iain Foulkes said: “The development of these Major Centres will accelerate national and international collaborations and improve treatments for patients.
“In each location, we are developing cutting-edge approaches in how we treat the disease, be that the detection of individual tumour cells in the blood that allow us to monitor the disease or precision radiotherapy.”